A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Wednesday, 18 April 2012

Atripla in Poland: a recent ruling on "product" and claim construction

Katarzyna Zbierska has kindly drawn our attention to this piece which was published in Special IP issue of the Bulletin of her law firm, Kochański Zięba Rąpała i Partnerzy:
"The Polish Supreme Administrative Court applies the definition of a “product” in the light of the CJEU’s judgments in the “Medeva” and “Georgetown” cases and Polish principles on patent claim construction
In its recently published reasoning to the judgment of 14 February 2012, the Polish Supreme Administrative Court (“SAC”) explains the grounds for upholding the judgment of the District Administrative Court in Warsaw (“DAC”), which ruled that the decision of the Polish Patent Office (“PPO”) on renouncing to grant an SPC for an antiretroviral product was correct. 
Merck & Co., Inc applied for an SPC for an antiretroviral product (“Atripla”) based on Polish patent PL 176679, which encompassed a new compound I or II and one nucleoside analog. The PPO stated that the basic patent concerned a product consisting of two active ingredients, whereas an SPC application concerned a product consisting of three active ingredients: efavirenz, emtrycitabine and tenofovir dizoproxil. The PPO decided that the product cannot be identified in the basic patent and tenofovir dizoproxil is a nucleotide analog whereas the subject matter of the basic patent is nucleoside analog. Since the patent claims do not refer to nucleotide analog or nucleoside analog prodrugs, the PPO decided that tenofovir dizoproxil does not fall within the claims of the basic patent. As a result, the PPO refused to grant an SPC. 

Merck challenged the argumentation raised by the PPO that patent claims, in particular in the case of inventions in the field of chemistry, may not be construed literally. Furthermore, the basic patent also covers products which consist of three active ingredients since the second ingredient specified in the patent claims has a functional character, thus encompasses any compounds which are biologically active. Claim construction applied by the PPO excessively limits the scope of the patent protection. The PPO does not take into account that patent protection encompasses not only ingredients indicated in the claims but also additional features, thus any combination of such ingredients may be considered a product qualifying for an SPC. 

According to Merck the claim no. 1 of the basic patent specifies a combination of ingredients having a formula I or II (in this case – efavirenz) with nucleoside analog being a reverse-HIV-transcriptase inhibitor (in this case nucleoside analog is: emtricitabine and tenofovir disoproxil fumarate). The claim does not refer only to one nucleoside analog since nucleoside analog reverse-HIV-transcriptase inhibitor concerns a group of compounds defined functionally. When editing patent claims a singular is commonly used, which however does not limit patent protection just to a single solution. The application of a nucleotide analog in combination which, after administration to a patient, transforms into a nucleoside analog falls into claim no.1 of the basic patent. The nucleotide analog is a nucleoside analog prodrug and is an equivalent to the solution covered by the basic patent.

The DAC upheld the PPO’s decision and decided that the claims of the basic patent concern a combination of active ingredients to prevent HIV infection characterized by that it is a combination of a formula I or II or pharmaceutically acceptable salts of formula I or II, with a nucleoside analog being a reverse-HIV-transcriptase inhibitor. According to the DAC, the basic patent covered only a two-ingredient combination: a combination of formula I or formula II with a nucleoside analog reverse-HIV-transcriptase inhibitor. The three-ingredient product being a combination of efavirenz, emtricitabine and tenofovir dizoproxil does not fall within the patent claims. One cannot derive from a teaching of the patent that it should cover more than two active ingredients. Neither do patent claims contain any “nucleotide analog” or “nucleoside analog prodrugs”. As a formula I, a formula II, their salts or nucleoside inhibitor one may use different compounds expressed by a particular formula or a functional name, though there will always be only two ingredients. Tenofovir dizoproxil fumarate is an additional active ingredient which renders the product new comparing to that included in the basic patent, beyond its scope of protection. 

Merck appealed the DAC’s verdict to the SAC which dismissed the appeal. According to the SAC, the scope of protection of the basic patent is determined by its claims. The Patent description and drawings should support claim construction, however, these are claims which are decisive when determining the scope of the patent protection. This means that claims should be construed literally and only what one can construe based on a patent document has a meaning. There is no basis to construe patent claims to the extent which a patent applicant did not take care of himself and seek protection which extends over the literal meaning of claims. This applies also to equivalents. It is important to remember that patent protection is not only a privilege for a patent owner but a limitation for others which should not encroach upon patent monopoly. Therefore, there must be and are limits of patent protection and this case has indicated this precisely. 
Granting an SPC over a product which is not entirely protected by the basic patent would in fact be contrary to Art. 3a of Regulation 1768/92. The SAC referred at this point to the judgments of the Court of Justice of the European Union of 24 November 2011 in cases C-322/10 (“Medeva”) and C-422/10 (“Georgetown”), in which the CJEU held that Art. 3a of the Regulation precludes the PPO from granting an SPC to active ingredients which are not specified in the wording of the claims of the basic patent relied on in support of the SPC application. Art. 3b of the Regulation does not preclude the PPO from granting an SPC for a combination of two active ingredients, corresponding to that specified in the wording of the claims of the basic patent relied on where the medicinal product for which the marketing authorization is submitted in support of the SPC application contains not only that combination of the two active ingredients (in the “Georgetown” case, C -422/10 – “that active ingredient”), but also other active ingredients. As a result, the material patent law has not been infringed in this case when determining scope of protection of the basic patent. 

According to the SAC, the subject matter of the basic patent is: a combination of two active ingredients, where active ingredient I is a particular compound I or II or their salt, and active ingredient II is a functional compound - nucleoside analog being a reverse-HIV-transcriptase inhibitor. Therefore, the second active ingredient must be from a group of nucleoside analog reverse-HIV-transcriptase inhibitors, however, one cannot derive from the claims of the basic patent that the combination may include two different nucleoside analogs, i.e. include a third active ingredient being another nucleoside analog. The basic patent did not encompass a combination of three active ingredients: efivarenz (compound indicated expressly in the patent claims), emtricitabine (nucleoside analog), tenofovir dizoproxil fumarate (nucleotide analog which transforms in a human body into another nucleoside analog). As a result, an SPC could not be granted for such a product which extends over the literal meaning of patent claims of the basic patent and thus does not meet the requirements under art. 3(a) of Regulation 1768/92".

Tuesday, 17 April 2012

Analysis of SPCs affected by Medeva

GenericsWeb recently undertook an analysis of all SPCs where the subject is a combination (with an expiry date after 01/01/2012), checking the underlying patents to see whether they protected all components of the combination specifically. They came up with some surprising results. The findings were presented at the European Generics Association legal affairs forum earlier this year, and are available in an article published in Generics Bulletin (here). You can also get a copy of the slides presented at the meeting by writing to y.bretonnet@genericsweb.com

Many thanks to Leighton Howard (GenericsWeb) for letting us know!

Monday, 16 April 2012

Seminar news

The SPC Blog pays particular attention
to getting the right alchemy for its seminars...
The programme for The SPC Blog Seminar, which Olswang LLP has kindly agreed once again to host in its London office, is nearly ready to go. The official programme and invitation will be posted very soon.  In the meantime, you might like to see how it's shaping up.

The date arranged for this year's event is Tuesday 22 May and the programme will look something like this:
13.30 Registration
14:00 Chairman's introduction
14:10 Medeva - the fall-out
14:35 SPC protection in Italy
15:00 Break
15:20 Neurim - the hearing and AG's opinion
15:40 SPCs, the central European patent and court
15:55 Medeva around the world and -- though this remains in the realms of possibility rather than certainty -- the SPC quiz!
16:20 Questions
Drinks and refreshments will then follow.

Don't respond to this post: just wait a bit and RSVP to the formal invitation!

Monday, 2 April 2012

The Neurim hearing: an eye-witness account

Francisco Bernardo Noriega (Partner, ABG Patentes, Madrid) is a patent attorney who works mainly in the field of pharmaceuticals. He recently attended the hearing before the Court of Justice of the European Union (CJEU) in the Neurim referral (Case C-130/11; see earlier SPC Blog posts here, here and here) which, in his view, deals with a number of interesting issues of SPC law. The case, he notes, is being closely followed by interested parties, as was evident by the surprisingly high number of members of the public attending in Luxembourg, including people from the pharmaceutical industry, solicitors and attorneys. This is what he writes:
“On 15 March 2012, the CJEU heard parties in connection with the C-130/11 Neurim Pharmaceuticals preliminary reference from the Court of Appeal for England and Wales. The reference concerns the interpretation of Articles 3(d) and 13 of the SPC Regulation (EC Regulation 469/2009) and, more particularly, the circumstances in which these Articles mean that an earlier marketing authorisation (“MA”) precludes an SPC based on a subsequent MA. In making the reference, the Court of Appeal had endorsed Neurim’s arguments in strong terms (“We consider that Neurim’s arguments are not only tenable: in our view they are right”), holding that Articles 3(d) and 13 should not preclude Neurim’s SPC, but that Neurim’s arguments needed endorsement by the CJEU:
“In short, if Neurim are wrong, then the Regulation will not have achieved its key objects for large areas of pharmaceutical research: it will not be fit for purpose. Whether that is so or not is clearly a matter for the EU’s highest court.”
Neurim, the UK Government, the Portuguese Government and the Commission appeared at the hearing in front of five judges (Jean-Claude Bonichot, Konrad Hermann Theodor Schiemann, Camelia Toader, Alexandra Prechal and Egidijus Jarašiunas) with Verica Trstenjak as the Advocate General.

Neurim and the Commission were united in arguing that an earlier MA should be taken into consideration (under Article 3(d) or Article 13) only if its subject-matter is within the scope of the basic patent (with reference to Article 4 which limits the scope of the SPC to being no broader than the basic patent). Both parties referred to the underlying scheme and objectives of the Regulation, highlighting the importance of incentivising the type of research which Neurim had undertaken and the consequences of not providing such incentives. They also drew distinctions over the existing case law (C-31/03 Pharmacia, C-431/04 MIT and C-202/05 Yissum etc.); they also emphasised that Neurim’s proposal for the operation of Articles 3(d) and 13 has never before been the subject of a CJEU judgment, and would allow the SPC regulation to meet its purpose, as defined in the recitals.

Neurim also referred to Recital 14 of Regulation 1610/96 (which is explicitly valid under Recital 17 for interpreting the medicinal product SPC Regulation), pointing out that failure to find in Neurim’s favour would deprive Recital 14 of its effet utile. Recital 14 states that an SPC can be granted for a patented salt even if there is an earlier SPC for the same active substance which would, were it not for Recital 14, block the second SPC (because, in such a case, the two active ingredients (“products”) are the same). In making this argument, Neurim referred to C-392/97 Farmitalia to demonstrate that one salt of a particular active ingredient is considered as having the same active ingredient (“product”) as another salt of the same active ingredient (or indeed the active ingredient in its non-salt form). Thus Neurim argued that Recital 14 could not operate properly if the CJEU rejected Neurim’s arguments because, if Neurim’s arguments were rejected, there would be situations where an earlier MA necessarily precludes an SPC based on a subsequently patented salt.

The UK argued that the CJEU has to find against Neurim because the CJEU’s existing case law constrains it from reaching any other conclusion. The UK referred in particular to C-31/03 Pharmacia, C-431/04 MIT and C-202/05 Yissum in addition to the recent cases of C-195/09 Synthon and C-322/10 Medeva. On Medeva, the UK argued that because the CJEU permitted an SPC to be based on an MA which refers to active ingredients (“A + B”) not specified within the scope of the patent (to “A”), it follows that Neurim is wrong. In reply, Neurim argued that the CJEU’s comments in Medeva (which formed the basis of the C-422/11 Novartis reasoned order) are entirely consistent with Neurim’s position because the CJEU confirmed that an SPC to “A” can be used to oppose “A + B” (i.e. “A + B” is within the protection conferred by an SPC to “A”, in accordance with patent law). On Synthon, the UK relied on the comments in AG Mengozzi’s opinion, and both the Neurim and the Commission put forward counterarguments.

The UK and Portugal also argued that Neurim’s approach could lead to evergreening. Both Neurim and the Commission disagreed, highlighting that any SPC granted under Neurim’s approach (which requires the basic patent not to extend to the subject-matter of the earlier MA) could not, by reference to Article 4, cover the subject-matter of the earlier MA. They therefore argued that the second SPC could not prevent the free movement of the earlier-authorised medicinal product within the European Community.

The Portuguese Government also considered that SPC availability in cases like Neurim would be contrary to TRIPS.

Neurim also argued that, if the CJEU answers the first three referred questions against it, then an SPC should nonetheless be allowed in those cases where the subsequent formulation/use requires a full marketing approval dossier (“Initial/Global Marketing Authorisation” according to art. 6(1) Directive 2001/83). Neurim highlighted the distinction between Initial/Global Marketing Authorisations as defined under European Pharmaceutical regulation and other authorisations which merely involve variations (and which, unlike an Initial/Global Marketing Authorisation, do not give rise to data exclusivity periods). This is reflected in the fourth question referred to the CJEU.

The Advocate General’s opinion is expected in May 2012, with the actual judgment of the Court likely to be issued several months later".
Thanks so much for this note, Francisco, which paints a colourful picture of the positions taken in this intriguing reference.

Tuesday, 27 March 2012

Plant protection patents and emamectin benzoate -- more news

Yesterday The SPC Blog posted this news from Hungary concerning a ruling of the Metropolitan Court of 12 January 2012 ("Plant SPC from earlier veterinary SPC? Yes, it can be done", submitted by James Horgan).

Today we are fortunate to have received some further information from our friend Alice de Pastors who writes:
To complete information on the Hungarian Plant Protection SPC for emamectin benzoate I wanted to point out three other Plant Protection SPCs for emamectin benzoate in Europe: Italy, Belgium and The Netherlands. 

In Italy and Belgium the SPCs refer to the Plant Protection first MA in The Netherlands, 13260 of December 4, 2009 (AFFIRM®) but in The Netherlands to the UK veterinary MA VM00201/453 MA (Slice®) with a date of March 9, 2010".
Thanks, Alice!

Monday, 26 March 2012

Plant SPC from earlier veterinary SPC? Yes, it can be done

"Can you get a plant SPC where there is an earlier veterinary SPC?" That's the question posed by James Horgan (Merck & Co., Inc. The answer, which he thoughtfully provides for us, is "Yes, say the Hungarians". The proof of this proposition may be found in a decision of the Metropolitan Court of 12 January 2012.

James has sent us a handy English translation from Danubia, which represented Merck Sharp & Dohme Corp. in the application. The patent, with a filing date of 2 April 1992, was for “Stable BLA/BLB salts of 4”-deoxy-4”-epi-methylamino avermectin”. To the SPC application there was attached, in addition to the basic patent on which the application was based, the first authorisation to place a composition called Slice on the market in the Community as a veterinary product (Vm00201/4153, United Kingdom, January 14, 2000); as a product the petitioner named an insecticide called Affirm (active ingredient: emamectin benzoate). To read what happened next, click here for the 8-page decision.

Friday, 23 March 2012

New book on the way

Last week The SPC Blog posted some news from Poland, kindly sent in by Katarzyna Zbierska (Partner, Legal Counsellor, Kochański Zięba Rąpała i Partnerzy, Warsaw).

Katarzyna has also sent us a link to her book, Application and Importance of Supplementary Protection Certificates in the European Union, which will be published in Aachen, Germany, next month by Shaker Verlag. Katarzyna's book is based on her Ph.D. thesis, which she completed at the University of Augsburg last May under the supervision of someone who is no stranger to this blog, Professor Dr Ulrich M. Gassner. The book's web page is here (though you might get hijacked on the way to that page by the front page of the publisher's search service. According to the Abstract:
"The book focuses on supplementary protection certificates for medicinal products (SPC) created on the basis of the Council Regulation (EEC) no. 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products (currently Regulation (EC) no. 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products). 
Since an SPC extends patent protection for a product, it provides an important advantage to innovative pharmaceutical companies in the European Union. The author discusses in detail various aspects of the legal mechanism of an SPC. She also presents similar legal concept in the USA as a benchmark for comparison of the European solution. The publication challenges the question of the importance and impact of an SPC on the European pharmaceutical market, among others, from a competition law perspective, as well as the role of an SPC in the context of other legal instruments available, such as market exclusivity and data exclusivity. This is particularly important as the current circumstances on the European pharmaceutical market differ much from those when the legal regime of the SPC was adopted. 
The publication also elaborates on the shortfalls of the current SPC system and identifies those areas which require amendments to address issues resulting from the rapidly changing situation on the pharmaceutical market in the European Union".

Patent term extension: to err is human

Hot off the press is this commentary by Israeli patent practitioner Michael Factor (Factor Patent Attorneys) on this week's Israeli decision in Patent Term Extension for 154325 submitted by Reinhold Cohen Patent Attorneys and Gilat Bareket Lawyers on behalf of Centocor Ortho Biotech Inc., before Jaqueline Bracha, Deputy Commissioner, 22 March 2012. Its contents will make uncomfortable reading for many a patent practitioner in private practice.

 As Michael -- not a man to pull his punches -- comments:
"From the affidavits submitted by employees of the agents for applicant ... it is clear that despite the firm being organized and having procedures in place to cover patent term extensions, there was human error. The deadline was missed and this was discovered seven months later.

Whether this is or is not fairly described as ‘unintentional’ or as the agent for applicant exhibiting ‘due care’, such circumstances cannot fairly be described as ‘circumstances over which the applicant and his representative had no control and which could not be prevented‘ unless one rules that human error is unavoidable. There was no earthquake or natural disaster to blame, there was no war, nor was there a postal strike. A paralegal and her supervisor both messed up. It happens ...".
Following the decision of the Deputy Commissioner in favour of the patent proprietor, Michael suspects that generic companies Teva or Unipharm might be considering an appeal.

Tuesday, 13 March 2012

Court upholds Polish Patent Office's "no" to QLAIRA

The SPC Blog has heard today from our good friend in Poland, Katarzyna Zbierska (Partner, Legal Counsellor, Kochański Zięba Rąpała i Partnerzy, Warsaw) about a recent reasoned ruling of the Warsaw District Administrative Court in Warsaw of 5 August 2011 (case no. VI SA/ Wa 87/11). In this ruling the court upheld a decision of the Polish Patent Office to refuse the grant of an SPC for a product distributed as the QLAIRA contraceptive (Bayer). Katarzyna explains that the ruling is worthy of mention as there are not many SPC cases in Poland, and it concerns the contentious issue of interpretation of a “product” definition.

The details of the case are described in the bulletin of her law firm's Intellectual Property Department, which you can access here.

Tuesday, 6 March 2012

Court of Justice sprints to reasoned order in Case C-422/11

A Court of Justice judge models
his new uniform ...
 The SPC Blog has received today a note from Brian Cordery (Bristows) concerning the Reasoned Order of the Court of Justice of the European Union in Case C-442/11Novartis v Actavis, this being a reference from the Patents Court, England and Wales (Floyd J), noted on this blog here. The Reasoned Order is dated 9 February but was only released to the parties' lawyers at the end of last week.

Brian observes that the operative part of the ruling [which is not yet available on Curia but you can read it in full, here] is as follows:
"Articles 4 and 5 of Regulation ... 469/2009 ...  concerning the supplementary protection certificate for medicinal products must be interpreted as meaning that, where a 'product' consisting of an active ingredient was protected by a basic patent and the holder of that patent was able to rely on the protection conferred by that patent for that 'product' in order to oppose the marketing of a medicinal product containing that active ingredient in combination with one or more other active ingredients, a supplementary protection certificate granted for that 'product' enables its holder, after the basic patent has expired, to oppose the marketing by a third party of a medicinal product containing that product for a use of the 'product', as a medicinal product, which was authorised before that certificate expired."
He adds, and this blogger agrees, that most SPC devotees will not be surprised by this ruling: it appears to be the logical consequence of the recent Court of Justice rulings in Medeva and Georgetown.

One point of interest is how (relatively) speedily the Court of Justice dealt with this reference. Admittedly, it didn't require detailed knowledge of the field of technology and the reference was on an issue on which it has been focusing a good deal in recent times, but the time between the referring court's decision to refer and the Court of Justice's order was little over eight months.

Thanks, Brian, for letting us know!